Peramivir is one of the most effective drugs that can be used to treat patients suffering from swine flu. During the H1N1 influenza epidemic crisis in 2009, the US Food and Drug Administration (FDA) awarded Peramivir with the Emergency Use Authorization. This particular drug was given special permission to be used in cases when all the other known methods of treatments for H1N1 fail to help the patients.
Important Usage of Peramivir
Peramivir was allowed to be used in intravenous form for the patients who were facing extreme conditions of swine flu. The specific emergency use authorization for this drug expired on June 24th 2010. During the emergency usage authorization period, Peramivir was not allowed to be administered orally, nor was it allowed to be administered with an inhaler as an antiviral therapy. Peramivir is the only drug that has been authorized by the FDA to be administered intravenously as an antiviral to effectively cure H1N1 and other lethal influenzas.
This experimental research molecule is available for R&D purposes from LGM Pharma’s Anti-Retroviral / Anti-HIVs therapeutic classification product category. Inquire about Peramivir CAS# 229614-55-5 prices, availability, delivery, purity and more.
Other usage of Peramivir
According to the latest scientific research, Peramivir is a neuraminidase inhibitor that reduces the process of influenza neuraminidase, which is necessary for the progression of influenza. By inhibiting neuraminidase, Peramivir prevents new viruses from emerging out of infected cells. By doing so, sick patients will not suffer further infection of influenza.
The United States Department of Health and Human Services (USDHHS) supports the development of Peramivir to be used as an effective influenza controlling drug to avoid any future threat of an influenza epidemic in the United States. This medicine is considered as the final solution for unresolved or unknown influenza illness. Because of its ability to prevent growth of any kind of influenza, this medicine can prove to be highly efficient in reducing the chances of pandemic threats of any influenza attack.
*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.